Attovia Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ATTO in the last 7 days.
No SEC Form 4 filings for $ATTO in the last 30 days.
See all $ATTO insider activity →Citi analyst Yigal Nochomovitz maintained a Buy rating on Attovia Therapeutics (ATTO) with a $30 target, while Morgan Stanley's Chris Quintero reiterated a Buy on Navan (NAVN) with a $33 target. Both stocks have Strong Buy consensus ratings and significant upside potential according to analysts.
Pro-Dex (PDEX) reported strong fiscal 2026 results with 17% Q4 sales growth and 16% annual sales increase. Modular Medical (MODD) gained FDA clearance for Pivot pump software. ENvue Medical (FEED) selected for Vizient Innovative Technology Exchange. Attovia (ATTO) and Pyxis Oncology (PYXS) provided clinical updates and financials. All stocks rose Friday.
Attovia Therapeutics reported a wider Q2 net loss of $20.69M ($4.88 per share) due to increased clinical costs, up from $14.44M a year ago. R&D expenses rose to $18.9M, while revenue was $0.45M. The company plans Phase 2 trials for ATTO-1310 in Q1 2027. Cash reserves total $115.13M. ATTO stock is up 4.20% at $24.12.
Recent ATTO coverage spans financial news, earnings and technology.
Potential upside of ~24% from current price may attract buyers.
Losses remain sizable; Phase 2 trial may improve long‑term outlook.
Quarterly loss widened and cash remains strong; early trial data are positive but no revenue guidance.
The company shows strong cash runway and early clinical validation, which may boost investor confidence.
New coverage bullish on immunology platform.
AlphAI scores every news story that mentions ATTO with an AI model for sentiment and relevance, and aggregates insider trades from Attovia Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Citi analyst Yigal Nochomovitz maintained a Buy rating on Attovia Therapeutics (ATTO) with a $30 target, while Morgan Stanley's Chris Quintero reiterated a Buy on Navan (NAVN) with a $33 target. Both stocks have Strong Buy consensus ratings and significant upside potential according to analysts.
2 min readPro-Dex (PDEX) reported strong fiscal 2026 results with 17% Q4 sales growth and 16% annual sales increase. Modular Medical (MODD) gained FDA clearance for Pivot pump software. ENvue Medical (FEED) selected for Vizient Innovative Technology Exchange. Attovia (ATTO) and Pyxis Oncology (PYXS) provided clinical updates and financials. All stocks rose Friday.
2 min readAttovia Therapeutics reported a wider Q2 net loss of $20.69M ($4.88 per share) due to increased clinical costs, up from $14.44M a year ago. R&D expenses rose to $18.9M, while revenue was $0.45M. The company plans Phase 2 trials for ATTO-1310 in Q1 2027. Cash reserves total $115.13M. ATTO stock is up 4.20% at $24.12.
2 min readAttovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of
2 min readAnalysts upgraded Deere (DE) to Outperform with a $800 target, citing strong North American demand. Abercrombie & Fitch (ANF) was upgraded to Buy with a $162 target after Q2 earnings beat. Agco (AGCO) upgraded to Outperform with a $150 target, expecting 2027 volume recovery. Kaiser Aluminum (KALU) upgraded to Buy with a $184 target. Stag Industrial (STAG) upgraded to Outperform. PG&E (PCG) downgraded by Wells Fargo and BMO. Mizuho downgraded PG&E, Sempra Energy (SRE), and Edison International (E
2 min readAttovia Therapeutics received bullish ratings from Citi, Morgan Stanley, and RBC, with price targets ranging from $30 to $45, citing promising early data for its chronic-itch drug ATTO-1310 and its antibody platform. The stock, trading around $21, has significant upside potential according to analysts. The company has $420M in cash post-IPO, reducing near-term financing concerns. Analysts caution about clinical-stage risks, including trial outcomes and competition.
2 min readWall Street analysts made several calls: Baird upgraded AGCO to $150 and Deere to $800, while Mizuho downgraded Edison International and Sempra Energy. Evercore ISI initiated Lumentum at Outperform with a $1,100 target, and Roth Capital started Ticketplus at Buy with a $14 target. Markets closed lower Friday due to Fed rate-hike concerns, with Treasury yields rising and major indices down.
7 min readAnalysts initiated coverage on five companies: Evercore ISI rated Lumentum (LITE) Outperform with $1,100 target; BTIG rated Smith & Nephew (SNN) Neutral; Morgan Stanley rated Attovia (ATTO) Overweight with $39 target; Roth Capital rated Ticketplus (TP) Buy with $14 target; Stifel rated Braveheart Bio (BRVE) Buy with $45 target.
1 min readMorgan Stanley initiated coverage on Attovia Therapeutics with an Overweight rating. Leerink Partners also started coverage with an Outperform rating and a $52 price target. The stock has seen a 5-day change of 20.70 USD, a 1st Jan change of -3.54%, and a year-to-date change of -0.48%.
1 min readRBC Capital Markets initiated coverage on Attovia Therapeutics with an Outperform rating and a $45 price target, citing speculative risk. The stock is currently trading at $20.70. Other analysts, including Morgan Stanley and Leerink Partners, have also initiated coverage with positive ratings.
1 min read
